Abstract: A sample rotating rack and a Raman spectrum detector are provided. The sample rotating rack comprises a rotating body and a plurality of sample carriers provided thereon, distributed around the circumference of the rotating body and able to be irradiated by light rays at the periphery of the rotating body. The Raman spectrum detector comprises a laser, a spectrum analyzer, a Raman probe, a rotating table and a sample rotating rack; the sample rotating rack is arranged on the rotating table, the Raman probe is arranged at the periphery of the sample rotating rack, and the Raman probe is electrically connected to the laser and the spectrum analyzer respectively; and the laser is used for emitting excitation light by means of the Raman probe, and the Raman probe can receive Raman scattered light and return same to the spectrum analyzer.

Abstract: Various examples described herein are directed to systems and methods of detecting damage to an analyte sensor using analyte sensor impedance values. In some examples, a method of assessing sensor membrane integrity using sensor electronics comprises determining an impedance parameter of an analyte sensor and determining a membrane integrity state of the analyte sensor based on the impedance parameter.

Abstract: Provided are sustained-release pharmaceutical compositions including a ketamine pamoate salt and a pharmaceutically acceptable carrier thereof. The compositions include aqueous suspension, solution and matrix delivery system, which can provide sustained release for anesthesia, analgesia or treatment of central nervous system and anti-inflammatory diseases.

Abstract: Methods, systems and computer readable media for responding to webpage requests are disclosed. The method includes: receiving a request to render a webpage, the webpage comprising a plurality of webpage components; identifying at least a subset of webpage components of the plurality of webpage components to be rendered by the server; rendering the identified webpage components at the server and converting to HyperText Markup Language (HTML); and communicating the HTML of the webpage components rendered at the server along with unrendered web components of the plurality of webpage components to a client device for displaying on a display of the client device. The client device includes a client browser configured to render the unrendered webpage components and display all webpage components on the display of the client device.

Abstract: The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides.

Abstract: The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides.

Abstract: The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides.

Abstract: The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.

Abstract: The described invention provides methods and kits for administering an EPO-derived peptide to a subject suffering from a neurodegenerative disease. The EPO-derived peptide delays the onset and/or progression of a neurodegenerative disease, limits cognitive impairment in, and prolongs the survival of, subjects suffering from a neurodegenerative disease.

Abstract: The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.

Abstract: The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides.

Abstract: The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.

Abstract: The present invention provides a cytotoxic MHC I conjugate comprising a cytotoxic moiety, biotinylated MHC I monomers which each comprise an antigenic peptide and streptavidin, bound to the cytotoxic moiety or to a biotinylated cytotoxic moiety and to the biotinylated MHC I monomers. Alternative constructs comprising a cytotoxic moiety and biotinylated MHC I monomers where each monomer comprises an antibody fragment also are provided. The cytotoxic moiety may comprise an 225Ac radionuclide or other cytotoxin. Further provided are methods of killing CD8+T cell clonal populations.

Abstract: The laser medical device includes a Nd:YAlO.sub.3 laser crystal; a pumping system which illuminates the laser crystal with light irradiated from a pumping light source and achieves population inversion of Nd.sup.3+ ion in the laser crystal; and a resonant cavity for resonating light emitted from the Nd.sup.3+ ion to output a laser light having a predetermined wavelength, wherein the wavelength of the laser light falls within the transparent range of quartz optical fibers. The laser medical device may also include a quartz optical fiber for transmitting the laser light; an optical fiber injector for focusing the laser light output by the resonant cavity on one end of the optical fiber; and an optical fiber pen which is coupled to another end of the optical fiber for aiming the laser light transmitted through the optical fiber at a desired location of a subject. These devices use Nd:YAlO.sub.3 crystal as an active laser material and output laser light having a wavelength, such as 1341.4 nm and 1079.